Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption
Acta Pharmaceutica Sinica B
; (6): 2384-2403, 2020.
Article
em En
| WPRIM
| ID: wpr-881119
Biblioteca responsável:
WPRO
ABSTRACT
The "vicious cycle" established between tumor growth and osteolysis aggravates the process of breast cancer bone metastasis, leading to life-threatening skeletal-related events that severely reduce survival and quality of life. To effectively interrupt the "vicious cycle", innovative therapeutic strategies that not only reduce osteolysis but also relieve tumor burden are urgently needed. Herein, a bone-seeking moiety, alendronate (ALN), functionalized coordination polymer nanoparticles (DZ@ALN) co-delivering cisplatin prodrug (DSP) and antiresorptive agent zoledronate (ZOL)
Texto completo:
1
Base de dados:
WPRIM
Aspecto:
Patient_preference
Idioma:
En
Revista:
Acta Pharmaceutica Sinica B
Ano de publicação:
2020
Tipo de documento:
Article